CNBX Pharmaceuticals Inc. reported earnings results for the third quarter and nine months ended May 31, 2023. For the third quarter, the company reported sales was USD 0.310165 million. Net loss was USD 0.15469 million compared to USD 0.681652 million a year ago. Basic loss per share from continuing operations was USD 0.02. Diluted loss per share from continuing operations was USD 0.02.
For the nine months, sales was USD 0.310165 million. Net loss was USD 3.14 million compared to USD 3.24 million a year ago. Basic loss per share from continuing operations was USD 0.78 compared to USD 2.65 a year ago. Diluted loss per share from continuing operations was USD 0.78 compared to USD 2.65 a year ago.